ArticleTargeted oncology2026

One-Week Inflammatory Kinetics After First-Line Nivolumab Plus Ipilimumab in Metastatic Renal Cell Carcinoma: A Multicenter Landmark Analysis.

Toru Inoue et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.